Figure 4. Effect of in vivo neutralization of IL-10 on the PLP139–151 16-mer treatment.
Oligomer treated mice were intraperitoneally injected with 0.5 mg of α-IL-10 or α-IL-10R (anti-IL-10 receptor). Injections were performed four times from the day of the treatment, every two days as indicated by the arrows. Untreated mice were used as control. Mice were monitored daily and the mean clinical score ±SEM was analyzed. These results are representative of two independent experiments. Statistical significance, **P<0.01 and *P<0.05 compared to PLP139–151 16-mer treated mice that were not administered anti-cytokine blocking antibodies. No effect was observed in oligomer treated mice given isotype control IgG1 antibody (Figure S2).